Skip to Main Content

Author Details

Jorge Silvio Gutkind
Moores Cancer Center, University of California San Diego
1984
511
116
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36596361Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.J Biol Chem2023
37961717YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.Res Sq2023
37858338High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.Cell Rep Med2023
37591955AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.Oncogene2023
37546810Direct reprogramming of oral epithelial progenitor cells to cancer stem cells at single cell resolution <i>in vivo</i>.bioRxiv2023
37774973Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor.J Biol Chem2023
37308665The GPCR-Gα<sub>s</sub>-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.Nat Immunol2023
37173324Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.Nat Commun2023
37339176Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.Cancer Res2023
36753744Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.Cancer Res2023
36787384Catalytic site mutations confer multiple states of G protein activation.Sci Signal2023
36869589CTLA-4 blockade induces tumor pyroptosis via CD8<sup>+</sup> T cells in head and neck squamous cell carcinoma.Mol Ther2023
36759733A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors.Nat Cancer2023
35103877Angiopoietin-2-induced lymphatic endothelial cell migration drives lymphangiogenesis via the β1 integrin-RhoA-formin axis.Angiogenesis2022
35639758PRECOGx: exploring GPCR signaling mechanisms with deep protein representations.Nucleic Acids Res2022
35790753Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy.Nat Commun2022
35456049Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.Cells2022
35779635Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1.J Biol Chem2022
35655319Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).J Exp Clin Cancer Res2022
36294681Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine.J Pers Med2022
36194164A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.Clin Cancer Res2022
36395141Somatic 9p24.1 alterations in HPV<sup>-</sup> head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.Proc Natl Acad Sci U S A2022
36321262Challenges and Emerging Opportunities for Targeting mTOR in Cancer.Cancer Res2022
35879302Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.Nat Commun2022
35217640Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER<sup>+</sup> breast cancer.Nat Commun2022
35086958Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs.Mol Cancer Ther2022
33096435Detecting cancer metastasis and accompanying protein biomarkers at single cell levels using a 3D-printed microfluidic immunoarray.Biosens Bioelectron2021
33603171Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis.Oncogene2021
33601339Insights into epithelial cell senescence from transcriptome and secretome analysis of human oral keratinocytes.Aging (Albany NY)2021
33568347Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
33562737Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.Cancers (Basel)2021
33888713Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.Nat Commun2021
34591613Interpretation of cancer mutations using a multiscale map of protein systems.Science2021
34725466EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.Commun Biol2021
34663687G<i>α</i>s-Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant G<i>α</i>s-PKA Signaling.Pharmacol Rev2021
34389658Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
34591642A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.Science2021
34324787Calcium signaling induces a partial EMT.EMBO Rep2021
34255745Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions.JCI Insight2021
33359448The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.Cancer Lett2021
31626727Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.Cancer2020
31848196HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.Cancer Res2020
31707029Activation of G-Protein Coupled Receptor-Gαi Signaling Increases Keratinocyte Proliferation and Reduces Differentiation, Leading to Epidermal Hyperplasia.J Invest Dermatol2020
33270228G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers.FEBS Lett2020
33291355Correction: Rigiracciolo, D.C., et al., IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. <i>Cells</i> 2020, 9, 1010.Cells2020
32763176Unleashing Immunotherapy by Targeting Cancer Stem Cells.Cell Stem Cell2020
32848210HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.Oncogene2020
32727882Tipifarnib as a Precision Therapy for <i>HRAS</i>-Mutant Head and Neck Squamous Cell Carcinomas.Mol Cancer Ther2020
33023908Gαs directly drives PDZ-RhoGEF signaling to Cdc42.J Biol Chem2020
32583739Nonmuscle myosin 2 regulates cortical stability during sprouting angiogenesis.Mol Biol Cell2020
  • 1 - 50 of 511

Recommended Authors

Tao Wei
Urumqi Friendship Hospital
Career Start Year 2005
Number of shared co-authors 0
Severa Bunda
Princess Margaret Cancer Centre
Career Start Year 2005
Number of shared co-authors 0
Genevi??ve Lavoie
Institute for Research in Immunology and Cancer (IRIC)
Career Start Year 2004
Number of shared co-authors 2
Yong Jae Shin
Cancer Stem Cell Research Center, Samsung Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 0
Mirko H H Schmidt
Institute of Anatomy, Technische Universitat Dresden School of Medicine
Career Start Year 2001
Number of shared co-authors 1
Hye Jin You
Research Institute, National Cancer Center
Career Start Year 2000
Number of shared co-authors 0
Stephane Angers
Department of Pharmaceutical Sciences, University of Toronto
Career Start Year 1999
Number of shared co-authors 4
Lawrence E Goldfinger
Cardeza Foundation for Hematologic Research, Thomas Jefferson University
Career Start Year 1998
Number of shared co-authors 0
Jong Bae Park
Henan-Macquarie University Joint Centre for Biomedical Innovation, Henan University
Career Start Year 1997
Number of shared co-authors 0
Mingyao Liu
The Institute of Biomedical Sciences, East China Normal University
Career Start Year 1994
Number of shared co-authors 0
Michael A White
University of Georgia
Career Start Year 1994
Number of shared co-authors 3
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 3
Karen H Martin
West Virginia University Cancer Institute, West Virginia University
Career Start Year 1993
Number of shared co-authors 0
Christoph Reinhard
Lilly Research Laboratories
Career Start Year 1992
Number of shared co-authors 1
Stephan M Feller
Institute of Molecular Medicine, Martin-Luther-University of Halle-Wittenberg
Career Start Year 1989
Number of shared co-authors 1
Dirk Geerts
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 0
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 0
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 6
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 12
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 9
Michael F Moran
Hospital for Sick Children, University of Toronto
Career Start Year 1985
Number of shared co-authors 4
Jeffrey L Wrana
Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital
Career Start Year 1985
Number of shared co-authors 1
Lucio Miele
Louisiana State University Health Sciences Center
Career Start Year 1983
Number of shared co-authors 4
Sylvain Meloche
Institute for Research in Immunology and Cancer
Career Start Year 1982
Number of shared co-authors 0
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 2
Michael C Ostrowski
Hollings Cancer Center, Medical University of South Carolina
Career Start Year 1979
Number of shared co-authors 0
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 4
Donald L Durden
Atrium Health-Levine Cancer Institute
Career Start Year 1979
Number of shared co-authors 7
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 45
Tony Hunter
Salk Institute for Biological Studies
Career Start Year 1968
Number of shared co-authors 9

Collaborators

Alfredo A Molinolo
University of California
Co-authored papers 80
Zhiyong Wang
Moores Cancer Center, University of California San Diego
Co-authored papers 25
Ezra E W Cohen
university of california san diego Health System
Co-authored papers 13
Joseph A Califano
University of California
Co-authored papers 13
Juan L Callejas-Valera
Cancer Biology Research Center
Co-authored papers 12
Nadia Arang
Moores Cancer Center, University of California San Diego
Co-authored papers 11
Scott M Lippman
Moores Cancer Center, university of california san diego
Co-authored papers 11
Yi Zheng
Children's Hospital Research Foundation
Co-authored papers 10
Mara Gilardi
Institute of Medical Genetics and Pathology.
Co-authored papers 9
Yusuke Goto
Chiba University Graduate School of Medicine
Co-authored papers 8
Xingyu Wu
Moores Cancer Center, University of California San Diego
Co-authored papers 7
Robert Saddawi-Konefka
Moores Cancer Center, University of California San Diego
Co-authored papers 7
Olivier Harismendy
University of California
Co-authored papers 7
Xiaoyuan Chen
Institute of Molecular and Cell Biology
Co-authored papers 6
Simone Lubrano
Moores Cancer Center, University of California
Co-authored papers 6
Michael M Allevato
University of Michigan Medical School.
Co-authored papers 6
Farhoud Faraji
University of California San Diego Health
Co-authored papers 6
Damiano Cosimo Rigiracciolo
European Institute of Oncology IRCCS
Co-authored papers 6
Jeffrey N Myers
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
William F Simonds
Co-authored papers 5
Kun-Liang Guan
University of California San Diego
Co-authored papers 5
Yansong Bian
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Jennifer R Grandis
University of California san francisco
Co-authored papers 4
Michael R Emmert-Buck
The Francis Crick Institute
Co-authored papers 4
Theresa Guo
Moores Cancer Center, University of California
Co-authored papers 4
Susan S Taylor
University of California
Co-authored papers 4
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 4
Pablo Tamayo
University of California San Diego
Co-authored papers 4
Adel K El-Naggar
MD Anderson Cancer Center
Co-authored papers 4
Release 1.2